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Abstract
The maintenance of glucose homeostasis within the body is crucial for constant and precise
performance of energy balance and is sustained by a number of peripheral organs. Estro-
gens are known to play a role in the maintenance of glucose homeostasis. Aromatase
knockout (ArKO) mice are estrogen-deficient and display symptoms of dysregulated glu-
cose metabolism. We aim to investigate the effects of estrogen ablation and exogenous
estrogen administration on glucose homeostasis regulation. Six month-old female wildtype,
ArKO, and 17β-estradiol (E2) treated ArKO mice were subjected to whole body tolerance
tests, serum examination of estrogen, glucose and insulin, ex-vivo muscle glucose uptake,
and insulin signaling pathway analyses. Female ArKO mice display increased body weight,
gonadal (omental) adiposity, hyperinsulinemia, and liver triglycerides, which were amelio-
rated upon estrogen treatment. Tolerance tests revealed that estrogen-deficient ArKO mice
were pyruvate intolerant hence reflecting dysregulated hepatic gluconeogenesis. Analyses
of skeletal muscle, liver, and adipose tissues supported a hepatic-based glucose dysregula-
tion, with a down-regulation of Akt phosphorylation (a key insulin signaling pathway mole-
cule) in the ArKO liver, which was improved with E2 treatment. Concurrently, estrogen
treatment lowered ArKO serum leptin and adiponectin levels and increased inflammatory
adipokines such as tumour necrosis factor alpha (TNFα) and interleukin 6 (IL6). Further-
more, estrogen deficiency resulted in the infiltration of CD45 macrophages into gonadal adi-
pose tissues, which cannot be reversed by E2 treatment. This study describes the effects of
estrogens on glucose homeostasis in female ArKO mice and highlights a primary pheno-
type of hepatic glucose dysregulation and a parallel estrogen modified adipokine profile.
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Introduction
Glucose homeostasis is maintained throughout the body via essential cross talk between
peripheral tissues. Elevated blood glucose levels following energy intake stimulate the release of
insulin from the pancreas which in-turn, stimulates glucose uptake into peripheral organs such
as skeletal muscle and adipose tissue. Additionally, the liver can produce glucose by glycogenol-
ysis (i.e. the breaking down of glycogen) and by gluconeogenesis (i.e. the de novo synthesis of
glucose from non-carbohydrate precursors such as lactate, pyruvate, glycerol and alanine). The
former occurs more rapidly, beginning within two to three hours after a meal in humans, but
the latter assumes a much greater importance with prolonged fasting [1,2]. Gluconeogenesis
can also be stimulated by glucagon or inhibited by insulin to maintain homeostasis [3]. Dysre-
gulated glucose homeostasis and obesity are key components of the metabolic syndrome
(MetS). Excess adipose tissue produces and secretes multiple adipokines including leptin, adi-
ponectin, resistin, visfatin; and in addition pro-inflammatory peptides, tumour necrosis factor
alpha (TNFα), interleukin (IL) 6 and monocyte chemoattractant protein (MCP) 1, which are
also released by invading macrophages commonly associated with obesity [4,5]. Adipokines
and free fatty acids (FFA) released from adipocytes can also play a role in maintaining glucose
homeostasis [3,6,7].
Both estrogens and androgens have been implicated in the modulation of various adipo-
kines. This can be observed when investigating clinical changes involved with menopause and
polycystic ovarian syndrome (PCOS). Postmenopausal women have low estrogens and this is
associated with dyslipidemia, increased central adiposity, serum leptin and inflammatory
markers with a decline in adiponectin [8]. The main source of estrogens after ovary senescence
in postmenopausal women is from aromatase conversion of androgens in peripheral tissues
such as adipose tissue and bone. Conversely, women afflicted with PCOS endure a state of
hyperandrogenism which results in increased adiposity, leptin, inflammatory markers TNFα
and IL6, and obesity independent decreases in adiponectin [9,10].
To elucidate the consequence of estrogen deficiency on glucose homeostasis and adipokine
profiles, we utilized the aromatase knockout (ArKO) mouse model, which was generated via
the deletion of exon 9 of the Cyp19A1 gene. Aromatase is the rate-limiting enzyme for convert-
ing C19 androgens to C18 estrogens and therefore the ArKO mouse is unable to produce estro-
gens; yet it is still responsive to estrogens through active estrogen receptors (ER). This model is
important because other models of estrogen deficiency, such as ovariectomy, retain the ability
to produce extra-gonadal estrogen due to aromatization at extra-gonadal sites. This makes the
ArKO a key model for investigating the effect of exogenous estrogen administration without
uncontrolled endogenous interference.
Materials and Methods
All efforts were made to minimize animal suffering and procedures were approved by the Mon-
ash Medical Centre Animal Ethics Committee (Permit Number: MMCB2008/08).
Mice
Aromatase Knockout (ArKO) mice (C57Black6 X J129) were generated by disruption of the
Cyp19A1 gene [11]. Homozygous null or wild-type (WT) offspring were bred by crossing het-
erozygous ArKO mice and were genotyped by PCR [12]. Mice were housed in groups under
pathogenic free conditions, fed a soy-free mouse chow (Glen Forest Stock feeders, Perth, Aus-
tralia) and water ad libitum as previously described [12]. Female WT and ArKO mice at 6
months of age were used in these studies (n = 7–20 as stated in figure legends).
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Estrogen and Sham Treatments
Each ArKO mouse was implanted with a 17β-estradiol pellet (E2; 0.15 mg in 60 days i.e. 2.5 μg/
day, for 6-weeks; Innovative Research of America, Toledo, OH, USA). No differences in body
mass, organ weights or glucose tolerance were detected between 6 month-old untreated ArKO
and littermates implanted with a placebo pellet (saline 60 day slow release; Innovative Research
of America, Toledo, OH, USA; see S1 Table and S1 Fig), hence untreated 6 month-old ArKO
female mice were used in this study. After treatment, mice were killed using a lethal dose of
anesthetic (100mg/ml Ketamine and 20mg/ml Xylazine in PBS). Blood was collected by cardiac
puncture and serum was separated, and stored at –20°C. Adipose, liver and muscle tissues were
removed, weighed and snap frozen in liquid nitrogen and stored at -80°C.
Insulin Stimulated Tissue Collection
Mice were anaesthetized (6mg pentobarbital sodium/100g body weight; Sigma, St Louis USA),
and injected with insulin (150 U/kg; Actrapid; Novo Nordisk, Bagsvaerd, Denmark) after fast-
ing overnight. Following a 5 min incubation, skeletal muscles (gastrocnemius, extensor digi-
torum longus, tibialis anterior and soleus), liver and gonadal fat were excised and rapidly
frozen in liquid nitrogen for storage at -80°C. Fasting blood samples were collected, serum sep-
arated and stored at -20°C.
Serum Estrogen Assay
Levels of 17β-estradiol in serum samples were measured in duplicates in a single RIA assay
using commercially available kits and protocols from Diagnostic Systems Laboratories (E2,
DSL-4800 ultra-sensitive; Webster, TX, USA). The theoretical sensitivity of detection was
2.2 pg/ml and the antibody used in this immunoassay was highly specific for 17β-estradiol.
The intra-assay coefficients of variation (CV) for E2 were8.9%.
Insulin Assay
Insulin was measured by ELISA (#EZRMI-13K, Linco Research, St. Charles, MO, USA) follow-
ing manufacturer’s protocol. Briefly, a 96-well microtitre plate pre-coated with monoclonal
mouse anti-rat insulin antibodies was washed thrice with kit wash buffer before incubation
with 10μl of control, standards or sample serum, plus a biotinylated anti-insulin antibody at
room temperature. Unbound material was washed away and horseradish peroxidase was
added to wells. Free enzyme conjugates were washed away and a light sensitive 3,3’,5,5’tetra-
methylbenzidine substrate added. Enzyme activity was measured spectrophotometrically at
450nm on the Envision Plate reader v 1.09 (Perkin Elmer, Waltham, MA, USA).
Tolerance Tests
All mouse cohorts were subjected to glucose tolerance test (GTT– 1g glucose/kg of body weight
i.p, after 8 h of fasting; Sigma, St Louis USA), insulin tolerance test (ITT– 0.5U insulin/kg of
body weight i.p., after 8 h of fasting; Actrapid; Novo Nordisk, Bagsvaerd, Denmark) and pyru-
vate tolerance test (PTT– 1g pyruvate/kg of body weight i.p., after ~16-20h of fasting; Sigma, St
Louis USA). At least five days of recovery were allowed between each test. Tail bleeding at spe-
cific time point was used to obtain blood samples which were analyzed for glucose content
(AccuChek Performer, Roche, Mannheim, Germany) immediately before, and at 20, 40, 60, 90
and 120 min after an intraperitoneal injection.
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Ex-vivo Muscle 2-deoxyglucose (2-DG) Uptake Assay
Soleus and extensor digitorum longus (EDL) muscles fromWT and ArKO mice were dissected
from anesthetized 6 month-old female mice and ex vivo 2-DG uptake was measured with or
without insulin (2.8 nM Actrapid; Novo Nordisk, Bagsvaerd, Denmark) as previously
described [13]. Muscle 2-DG uptake was measured by liquid scintillation counting (Tri-Carb
2000, Packard Instrument) of the muscle lysate/supernatant which was prepared by homogeni-
zation of the tissue sample in ice-cold protein lysis buffer (50mMHEPES, pH 7.4, 150mM
NaCl, 10mM NaF, 1mM sodium pyrophosphate, 0.5mM EDTA, 250mM sucrose, 1mM DTT,
1mMNa3VO4, 1% Triton X-100 and 1 Roche protease inhibitor tablet per 50ml) followed by
centrifugation at 4°C, 13,000 rpm for 30 min and collected.
Western Analysis
Ice-cold protein lysis buffer (2.5mMHEPES, 68.5mM NaCl, 0.5mMMgCl2, 0.5mM CaCl2,
5mMNaF, 1mM EDTA, 5mMNa pyrophosphate, 1mMNaVO4, 0.5% Nonidet P40, and 5%
glycerol) containing protease inhibitors (Complete Mini; Roche, Mannheim, Germany) was
incubated with tissue samples for 45 min on ice as a form of homogenization. Lysate superna-
tants were collected after centrifugation at 14,000g for 15 min, and stored at -20°C. Protein
content was determined by the bicinchoninic acid (BCA) method (Pierce Biotechnology, Rock-
ford, IL, USA). Protein samples (50μg) added to 1× sample loading buffer (0.125M Tris-Cl, 4%
SDS, 20% v/v Glycerol, 0.2M DTT, 0.02% Bromophenol Blue, pH 6.8), heated for 5 min at
95°C, separated by SDS-PAGE (10% polyacrylamide resolving gel and 4% stacking gel) and
transferred to a nitrocellulose membrane (Amersham GE Healthcare, Piscataway USA). Pri-
mary antibodies diluted in 1% BSA in Tris Buffered Saline with 1% Tween were incubated
rocking overnight at 4°C (mouse anti-Phospho-Akt (Ser473) 1:1000, rabbit anti-Akt 1:1000;
Cell Signaling Technologies, Beverly MA, USA). Appropriate Alexa Fluor secondary antibodies
were incubated at room temperature for 1 h. Protein band intensities were quantified using the
Odyssey infrared imaging system (Licor Biosciences, Lincoln, NE, USA). All protein quantifi-
cations were normalized to housekeeping protein β-tubulin (mouse anti-β-tubulin; 1:10,000,
Millipore, California USA).
Real-time PCR
Total RNA was extracted from mouse gonadal adipose and liver tissues using RNeasy RNA
extraction kit (QIAGEN, Duesseldorf, Germany) and Ultraspec RNA isolation system (Fisher
Biotec, WA, Australia) following manufacturers’ protocols, respectively. All RNA samples were
DNase I treated (DNAfree, Ambion, Foster City, CA, USA). Total RNA concentrations were
quantified spectrophotometrically using the NanoDrop1000 (Thermo, Willmington, USA).
cDNA derived from reverse transcription (Roche, Mannheim, Germany) of 1μg of RNA was
diluted 10-fold and amplified by real-time PCR in the ABI7900H (Applied Biosystems, Califor-
nia) using a SYBR ‘Master Mix’ (DMSO (Sigma) 10X Gold PCR Buffer, AmpliTaqGold
(Applied Biosystems), 1MMg(oAC)2 (Sigma), 100mM dACT, dCCT, dGCT and dTCT (Bio-
line) 1μg/μl 6-ROX and 10,000X con SYBR (Invitrogen)0, with specific oligonucleotide pairs:
Adiponectin (F:5’TGTTGGAATGACAGGAGCTGA3’, R:5’CACACTGAAGCCTGAGCGA
TAC3’); Interleukin-6 (IL6) (F:5’ATGGATGCTACCAAACTGGAT3’, R:5’TGAAGGACTC
TGGCTTTGTCT3’); Leptin (F:5’TCCAGAAAGTCCAGGATGACAC3’, R:5’CACATTTTGG
GAAGGCAGG3’);
Monocyte chemoattractant protein 1 (MCP-1; also referred to as chemokine (C-C motif)
ligand 2, CCL2) (F:5’CCACTCACCTGCTGCTACTCA3’, R:5’TGGTGATCCTCTTGTAGCTC
TCC3’); tumour necrosis factor α (TNFα) (F:5’CTCTTCAAGGGACAAGGCTG3’, R:5’GGAC
Estrogens, Adipokines and Glucose Homeostasis in Female ArKOMice
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TCCGCAAAGTCTAAG3’). Real-time PCR data were calculated using ΔΔCT method of analy-
sis. All samples were normalized to housekeeping gene cyclophilin (F:5’CTTGGGCCGCGTC
TCCTTC3’, R:5’TGCCGCCAGTGCCATTAT3’) transcript levels.
Adipokine Level Assays
Adipokine levels in mouse serum samples were analysed using the adipokine LINCOplex Kit
96 well assay according to manufacturer’s protocol (Mouse Serum single-plex adiponectin
panel #MADPK-71-ADPN; Mouse Serum Adipokine kit #MADPK-71K –leptin, MCP1,
TNFα, IL-6, PAI and insulin; Millipore, California USA). Thawed serum samples were vor-
texed and centrifuged before use. Mouse adipokine standards and quality control cocktails pro-
vided were reconstituted in deionized water. Briefly, standards, quality controls and serum
samples were pipetted into individual wells of the 96-well microtitre filter assay plate in dupli-
cates after assay plates had been washed in a 1× wash buffer with a vacuum manifold filtration
unit (Millipore, California USA). After 4°C overnight incubation with antibody immobilized
beads, plates were washed before mouse adipokine detection antibodies were added, and incu-
bated for 30 min. Unhybridized antibodies were washed off before Streptavidin-Phycoerythr-
ine were added and incubated at room temperature for 30 min. After Luminex sheath fluid was
added, plates were scanned and analysed on the Luminex 100 instrument and software (Lumi-
nex Corporation, Texas, USA).
Liver Tissue Triglyceride (TG) Content
Saponified extracts were prepared from frozen liver samples, and the triglyceride content was
quantified by comparison to a glycerol standard curve as previously described [14]. Hepatic tri-
glycerides (TG) were extracted by digesting 100–300 mg liver tissues overnight at 55°C in etha-
nolic potassium hydroxide (2:1 vol/vol of 100% ethanol and 30% potassium hydroxide) [15].
Samples were neutralized with water:ethanol (1:1 vol/vol). After centrifugation (8,000×g,
5 min), supernatant was collected and further diluted to 1.2ml with water:ethanol, of which
200μl proceeded to saponification with 215μl 1MMgCl2 by vortexing briefly and incubating at
4°C for 10 min. Saponified liver extracts (the upper phase) were separated by centrifugation,
and the glycerol content was quantified by mixing 6μl extract with 200μl Free Glycerol Reagent
(Sigma-Aldrich, Missouri, USA), which would react with free endogenous glycerol to generate
a dye with an absorbance at 540nm. Absorbance (measured using the Wallac 1420 Victor Plate
Reader, LabX, Midland ON Canada) is directly proportional to free glycerol concentration of
the sample. All blanks (6μl water), glycerol standards (6μl diluted 1:3; Sigma-Aldrich, Missouri,
USA) and samples were quantified in duplicates.
Immunohistochemistry
Paraffin embedded gonadal adipose tissues were sectioned (5μm), dewaxed in histosol (Sigma-
Aldrich) and rehydrated in a graded series of ethanol. Sections were microwaved at high power
(700 W) in 0.01 M citric acid buffer (pH 6.0) for 5 min. Endogenous peroxidase activity was
quenched with 6% H2O2 in 100% methanol (1:1 v/v) for 10 min. Tissues were incubated with
non-immune blocking solution (10% normal horse serum, 2% normal mouse serum) diluted
in 1×Tris-buffered saline for 30 min. The primary antibody; rabbit polyclonal CD45 (Abcam
#ab10558) or non-immune goat IgG (isotype negative control, DakoCytomation) were applied
at 1μg/ml in blocking solution for 18 h at 4°C, followed by biotinylated goat anti-rabbit IgG
(Dako 1:200) for 30 min, then streptavidin–biotin–peroxidase complex ABC (DakoCytoma-
tion Glostrup, Denmark) according to the manufacturer's instructions. Peroxidase activity was
visualized by application of diaminobenzidine substrate (DakoCtyomation) for 2 min. Tissues
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were counterstained with Harris haematoxylin (Sigma), air dried and mounted. A quality con-
trol slide was present in each immunohistochemistry run. Five representative photographs at
20× magnification were taken from each tissue section (n = 5 animals per group) using Cell-
Sense software (Olympus). The number of CD45 positive cells per field were counted and aver-
aged for each tissue by an observer who was blind to the genotypes and treatment.
Statistical Analysis
All statistical analyses were performed using GraphPad Prism version 5.04 for Windows (Graph-
Pad Software Inc). Data were analyzed using a two-tailed t-test or Mann-Whitney test depending
on the outcome of Shapiro-Wilk normality test. Since the data of body weight, liver triglyceride,
serum glucose, adipocyte leptin and adiponectin, and ex-vivo muscle glucose uptake passed the
Shapiro-Wilk normality test, they were analyzed by two-tailed t-test. Other data were analyzed
by two-tailed Mann-Whitney test. Data are expressed as mean ± standard deviation (SD). Differ-
ences between groups are considered statistically significant if p-value<0.05.
Results
The effects of estrogens on body and tissue weights
Untreated female ArKOmice were significantly heavier thanWT controls (Table 1), and, their
gonadal (omental) adipose tissue accumulation was higher (p<0.05, Table 1) thanWT. 17β-estra-
diol (E2) treatment (2.5μg/day) led to a reduction in body weight and gonadal adipose tissue
weights compared to both untreated ArKO (p<0.05, p<0.01; Table 1) andWT littermates
(p<0.05, p<0.01; Table 1). Untreated ArKO uteri were significantly reduced in wet weight
(p<0.01) as compared to theWT counterparts. Upon E2 treatment, ArKO uterus weight surpassed
that of WT size (p<0.0001 vs. ArKO). Female ArKO livers tended to be heavier than theWT livers
(p = 0.053, Table 1) but no differences were seen in liver weights between ArKO+E2 andWT.
Serum estrogens levels
Serum estrogens in untreated ArKO mice are undetectable. After 6 weeks of E2 treatment,
serum estrogen levels in the ArKO mice were increased compared to both the untreated ArKO
andWT mice (p = 0.05; Table 1).
Table 1. FemaleWT, ArKOmouse body, tissue weights, serum 17β-estradiol levels and liver triglycerides levels.
WT KO KOE
Number of mice 7–10 7–10 6–13
Body weight (g) 26.74±2.606 32.21±9.85* 27.14±3.78#
Gonadal/Omental adipose weight (g) 0.71±0.19 1.14±0.5* 0.36±0.35**##
Uterus weight (g) 0.11±0.01 0.01±0.003** 0.27±0.25###
Liver weight (g) 1.04±0.18 1.47±0.76 (p = 0.053 vs WT) 1.21±0.13
Serum 17β-estradiol (pM) 13.02±4.51 Not detectable 136.7±209 (p = 0.051 vs WT)
Liver Triglycerides (mg/ml) 0.84±0.33 1.96±1.42* 0.63±0.22#
Body, gonadal adipose tissue, and uterus weights in grams (g) of 6 month-old female wild type (WT), Aromatase knockout (KO) and 2.5μg/day 17β-
estradiol-treated ArKO (KOE). Serum estrogen levels were measured (pM) in 6 month-old female WT, KO and KOE animals. Liver triglycerides were
measured (mg/ml) in 6 month old female WT, KO and KOE. Data are expressed as mean ± SD
* p<0.05, and
**p<0.01 versus WT mice.
#p<0.05
##p<0.01
###p<0.001 versus ArKO.
doi:10.1371/journal.pone.0136143.t001
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Liver triglyceride levels
Mean liver triglyceride levels of untreated ArKO (1.96 mg/ml) are more than 2-fold higher
(p<0.05) than that of WT (0.84 mg/ml), which were returned to WT levels upon E2 treatment
(0.63 mg/ml; p<0.05 vs untreated ArKO; Table 1).
Whole body glucose, pyruvate and insulin tolerance in the ArKOmice
Basal fasted serum glucose levels were similar amongst the 3 groups of mice (Fig 1A). However,
20 min after glucose challenge, untreated ArKO mice serum glucose levels were significantly
higher (p<0.05) thanWT counterparts, and E2 treatment attenuated this increase (Fig 1A).
Basal fasted serum insulin levels were increased in the ArKO mice (p<0.05) and was reduced
upon E2 treatment (p<0.05; Fig 1B).
No significant differences were seen in area under the curve (AUC) for whole body glucose
and insulin tolerance tests between all 3 groups (data not shown). Untreated female ArKO
mice displayed significantly higher pyruvate intolerance (p<0.001 AUC, Fig 2) compared to
WT. Upon E2 treatment, the ArKO mice no longer show higher pyruvate intolerance as com-
pared to WT, suggesting that the primary metabolic defect in ArKO mice is related to elevated
hepatic gluconeogenesis.
The role of estrogens and androgens in ex-vivo muscle glucose uptake
Consistent with the idea that the liver was the primary site of metabolic dysfunction, muscles
(EDL and soleus) from both untreated ArKO and WTmice showed similar efficacy in basal or
insulin stimulated glucose uptake ex vivo (Fig 3A and 3B). The validity of this experiment was
confirmed by significant increases of the glucose uptake observed in insulin stimulated muscles
compared to vehicle treated muscles in both WT and KO genotypes (soleus, p<0.001 and
0.001 respectively; EDL, p<0.01 and 0.01 respectively). Since ArKO mice have higher serum
androgen levels [16], we further examined the direct effects of dihydrotestosterone (DHT,
100nM) on the glucose-uptake of six month-old WT soleus and EDL muscles in the ex vivo
Fig 1. Serum glucose and insulin levels. (a) Fasted basal serum glucose and 20 min after glucose challenge serum glucose levels; (b) Fasted basal serum
insulin (from 6 month-old female WT (wild type), KO (aromatase knockout) and KOE (aromatase knockout treated with 2.5µg/day 17β-estradiol) mice. Data
are expressed as mean ± SD (n = 5–13 per group).
doi:10.1371/journal.pone.0136143.g001
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experiment. No differences were found in soleus nor EDL insulin stimulated glucose uptake
between vehicle and DHT treated muscles (Fig 3C, P>0.05) supporting the idea that androgens
have little effect on muscle insulin sensitivity.
Gonadal adipose tissue, liver and muscle Akt protein phosphorylation
To determine the potential mechanisms responsible for differences in glucose homeostasis, the
expression and phosphorylation levels of Akt (a critical component of canonical insulin signal-
ing) was measured in gonadal adipose, skeletal muscle and liver tissues of six month-old WT
and ArKO female mice after an i.p. injection of insulin. Consistent with our metabolic data
indicating defects in liver glucose homeostasis, we found that liver Akt phosphorylation was
significantly decreased (p<0.05) in the untreated ArKO mice compared to the WT and was
restored with E2 administration (Fig 4A). There were no differences in Akt phosphorylation in
adipose tissue or skeletal muscle (Fig 4B and 4C).
Adipokine expression levels in female ArKOmice
To examine the mechanisms potentially contributing to the development of liver insulin resis-
tance in ArKO mice, we examined serum adipokines and markers of inflammation. Serum lep-
tin levels in untreated ArKO mice tended to be increased as compared to WT, whilst leptin
transcript levels were significantly increased in the gonadal adipose tissue (p<0.05; Fig 5A and
5D). After E2 treatment, ArKO serum leptin levels (p<0.01 and p<0.01) as well as transcript
levels (p<0.001 and p<0.001) were lowered as compared to both ArKO and WT respectively
(Fig 5A and 5D).
Both serum adiponectin and adipose adiponectin transcript levels were similar in the
untreated ArKO and WT littermates (Fig 5B and 5E). Unexpectedly, E2-treatment significantly
decreased serum adiponectin and adipose adiponectin mRNA levels compared to both WT
and untreated ArKO mice (p<0.01 and p<0.01 respectively).
Levels of serum inflammatory adipokines TNFα, IL6 and MCP1 remained comparable
between untreated female ArKO and their WT littermates (Fig 5C) although significant
Fig 2. Whole body glucose, insulin and pyruvate tolerance. (a)Whole body tolerance tests were completed on fasted 6 month-old female wildtype (WT)
and aromatase knockout (KO) and 2.5μg/day 17β-estradiol-treated KO (KOE) pyruvate tolerance test and (b) corresponding area under curve. Data are
presented as the mean ± SD. (n = shown on corresponding bar/ group) *p<0.05, **p<0.01, and ***p<0.001 versus expression in WT samples and # p<0.05
and ##p<0.01 versus KO samples.
doi:10.1371/journal.pone.0136143.g002
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increases in adipose TNFα and MCP1 transcript levels (p<0.05 and p<0.01 respectively) were
detected. Following E2 treatment, serum inflammatory markers TNFα and MCP1 showed sig-
nificant increases (p<0.01 and p<0.05 respectively) compared to WT littermates. This same
trend was observed for serum IL6 (p<0.1) when ArKO mice were treated with E2 (Fig 5C).
While adipose TNFα and IL6 mRNA levels were increased following E2 treatment (p<0.01
and p<0.01) compared to WT, MCP1 mRNA levels remained comparable to WT levels (Fig
5F). No differences in serum Plasminogen Activation Inhibitor (PAI) were observed between
all treatment groups (data not shown).
Fig 3. The role of estrogens and androgens in ex-vivomuscle 2-deoxy-glucose (2-DG) uptake. Six month-old wildtype (WT) and aromatase knockout
(KO) female ex vivo 2-DG uptake in basal or insulin stimulated (a) soleus and (b) EDL muscle extractions. Data are presented as mean ± SD (n = 7/group).
**p<0.01 and ***p<0.001 expression in basal versus insulin stimulated muscle. Six month-old wildtype (WT) female ex vivo glucose uptake in (c) vehicle or
dihydrotestosterone (DHT) (100nM) treated soleus and EDLmuscle extractions. Data are presented as mean ± SD (n = 7/group).
doi:10.1371/journal.pone.0136143.g003
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Macrophages in gonadal/omental adipose tissue
A possible contributing source of inflammatory adipokines besides adipocytes is adipose asso-
ciated macrophages which are CD45 positive [17]. Thus, we used CD45 immunostaining to
examine the extent of macrophage invasion into the gonadal adipose tissue (Fig 6A). CD45
positive cells were significantly increased in untreated ArKO mice as compared to WT
(p<0.05; Fig 6B). E2 treatment in the ArKO mice was unable to reduce CD45 positive cell pop-
ulation (p = 0.058 vs WT).
Discussion
The role of estrogens in the regulation of glucose homeostasis has been extensively studied as
recently reviewed by Kim et al. and Mauvais-Jarvis et al. [18,19]. However, defining the mecha-
nisms by which exogenous estrogens affect glucose homeostasis, without the interference of
endogenous production, has yet to be elucidated. This is important when considering the
effects of hormone replacement therapy for menopause (when the ovaries, the main source of
estrogens within the body, have ceased hormone production).
This is the first study to use whole body tolerance tests in female ArKO mice to measure
whole-body glucose homeostasis. Female ArKO mice showed an increase in gonadal adipose
tissue, serum glucose 20 min after glucose challenge, and fasted basal insulin levels compared
to WT counterparts, indicating defects in glucose homeostasis. Pyruvate tolerance tests indi-
cated that the primary defect in glucose control was attributed to elevated hepatic gluconeogen-
esis in female ArKO mice. In comparison, previous studies of themale ArKO mice showed
similarly increased adiposity and serum glucose as well as glucose and pyruvate intolerance
[20].
Higher liver triglycerides, which were reduced upon estrogen treatment, in the female
ArKO mice also support recent finding that liver fat is the best predictor of liver insulin sensi-
tivity [21]. Consistent with this finding, treatment of female ArKO mice with insulin revealed
significant reduction in liver phosphorylation of Akt, the primary signal controlling hepatic
gluconeogenesis. These effects appear to be independent of changes in systemic inflammation.
Fig 4. Insulin stimulated Akt protein phosphorylation in liver, adipose and skeletal tissues. Six month-old female wildtype (WT) and aromatase
knockout (KO) and 2.5μg/day 17β-estradiol-replaced KO (KOE) mice were used. Protein phosphorylation analyses of Akt levels were performed on protein
extracted from insulin stimulated (a) liver, (b) adipose tissue and (c) skeletal muscle. Data are presented as mean ± SD (n = 6-8/group). **p<0.01 versus
expression in age-matchedWT samples and #p<0.05 versus expression in age-matched ArKO untreated samples.
doi:10.1371/journal.pone.0136143.g004
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Although, no changes were seen in whole body glucose or insulin tolerance (AUC) between
the female ArKO and WTmice, the former were found to be pyruvate intolerant. Upon further
investigation of peripheral tissue involvement, we revealed a sensitivity of the liver to the pres-
ence of estrogens. Liver Akt phosphorylation in the ArKO mouse was decreased and improve-
ments were noted upon E2 treatment. Akt is a key downstream mediator in the insulin
signaling pathway and is able to mediate reductions in gluconeogenesis via PGC1α inhibition
[22] and FOXO1 phosphorylation [23,24]. These factors combined suggest signs of hepatic
insulin resistance in the ArKO mouse. This hepatic phenotype of glucose intolerance along
with modifications to genes involved in gluconeogenesis, insulin signalling and lipid synthesis
were also seen in the male ArKO mice as previously published [20].
Further analysis of the ArKO peripheral tissues also suggested that there may be a role for
the adipose tissue in the dysregulation of glucose homeostasis seen in the female ArKO mice.
In the adipose tissue, the production of adipokines revealed a negative correlation between
increased leptin with decreased estrogen levels in the ArKO mice as noted previously [25].
Estrogens are a known stimulator of leptin expression as evident by fluctuations during the
Fig 5. Serum adipokine and gonadal adipose tissue adipokine transcript levels. Serum adipokine analyses of (a) leptin, (b) Adiponectin and (c) TNFα,
IL6 and MCP1 concentrations were performed on serum from six month-old female wildtype (WT), Aromatase knockout (KO) and 2.5μg/day 17β-estradiol-
treated KO (KOE) mice. Data are presented as mean ± SD (n = 6/group). *p< 0.05, **p<0.01, versus expression in age-matchedWT samples and ##p<0.01
verses KO samples. Real-time-PCR analyses of (d) Leptin, (e) Adiponectin, (f) TNFα, IL6 and MCP1 gene expression were performed on cDNA derived from
total RNA prepared from gonadal adipose tissue of six month-old female wildtype (WT), Aromatase knockout (KO) and 2.5μg/day 17β-estradiol-treated KO
(KOE) mice. Data are presented as mean ± SD (n = 7/group). following normalization to cyclophilin *p<0.05, **p<0.01, ***p<0.001 versus expression in
age-matchedWT samples and ##p<0.01 and ###p<0.001 verses KO samples.
doi:10.1371/journal.pone.0136143.g005
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estrus cycle, and inhibition upon administration of the anti-estrogen drug tamoxifen [26–28].
Thus, the increased leptin expression in the ArKO mice and its prominent reduction upon
estrogen treatment are more likely an effect of changes in excessive gonadal adiposity than a
direct effect of estrogens. By contrast, adiponectin levels were reduced in the ArKO mice with
E2 administration in accordance with previous in vivo [29,30] and in vitro [31] studies demon-
strating the estrogen suppression of adiponectin. This suggests that estrogen action on adipo-
nectin, which is an insulin sensitizer, may play an important role in glucose homeostasis. Choi
et al. [32] described the role of PPARγ, causing direct upregulation of adiponectin. On this
note, we have previously reported that E2 administration in the ArKO mouse leads to
decreased PPARγ expression [33], which may cause the reduction in adiponectin we observed.
Another possible mechanism for reducing adiponectin in the E2 treated ArKO was the
observed increases in serum inflammatory markers TNFα, IL6 and MCP1, which are all
known inhibitors of adiponectin.
Fig 6. CD45 Immunohistochemistry of gonadal adipose tissues. (a)Representative CD45 immunohistochemistry staining of gonadal adipose tissues
from six month-old female wildtype (WT), aromatase knockout (KO) and 2.5μg/day 17β-estradiol-treated KO (KOE) mice; (b) quantitated CD45-positive cells.
Data are presented as mean ± SD (n = 5/group). *p< 0.05, versus age-matchedWT samples.
doi:10.1371/journal.pone.0136143.g006
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Although E2 replacement in many cases of estrogen deficiency, such as menopause and
ovariectomy, results in reduced adiposity and inflammation [34,35]; there are cases whereby
estrogens can play a negative role in the development of inflammation. High or supra-physio-
logical levels of estrogens as seen in third trimester pregnancy [36] are associated with increases
in TNFα and leptin concentrations in addition to decreased adiponectin [37]. Riant and col-
leagues [38] also found increase in TNFα, IL6, MCP1 and F480 in ovariectomised mice on a
high fat diet when treated with estrogens. Macrophage density was also increased in adipose
tissue in this model which may account for the increased capacity of macrophages to produce
cytokines [38]. Direct modulation of inflammation by estrogens is corroborated by the location
of estrogen receptors (ERs) on cells of the immune system [39] and have been associated with
modulating immune cell recruitment into estrogen sensitive tissue such as the uterus [40,41].
Subsequent increased MCP1 concentration observed in the female ArKO serum with E2
treatment and increased CD45 positive cells in the adipose tissue of female ArKO and ArKO
+E2 mice suggest enhanced macrophage infiltration from the periphery which may explain the
increases in serum and adipocytes TNFα and IL6 in these animals. However, the discrepancies
between serum and adipose tissue MCP1 levels could be explained by the fact that MCP1 is not
exclusively produced by adipose tissue [42]. Indeed, our data support the observation that
estrogen actions on inflammation are still dependent on a myriad of factors such as target
organ, concentration (biphasic effects) and the ER isoforms present [43]. Estrogens may be act-
ing through ERα instead of ERβ to exert changes in adiposity since ERαKOmice of both sexes
present increased adiposity but not ERβKOmice (for review see reference [15]); the former
presents similar adiposity phenotypes to our estrogen-deficient ArKO mouse model [25].
Estrogen deficiency had neither inhibitory modifications in muscle or adipose Akt phos-
phorylation nor insulin stimulated ex vivo skeletal muscle glucose uptake. The high HDL levels
[44,45] in female ArKO mice may counteract any reductions in Akt associated with insulin
resistance in muscle and adipose tissues, leading to no significant changes in Akt phosphoryla-
tion in these ArKO tissues when compared to the WT.
Conclusion
The ArKO mouse is an important estrogen responsive model which allows us to examine exog-
enous estrogen dosage on the relationship between hormones, adiposity and insulin resistance
without the interference of uncontrolled endogenous estrogen production. Our observations
provide an understanding into the complex mechanisms, including changes in Akt, TNFα, IL6
and MCP1 by which estrogen regulates obesity and insulin resistance. Estrogen administration
in the ArKO mice leads to improvements in liver glucose homeostasis. However, simultaneous
displays of increased inflammatory processes in the adipose tissue adipokines may be responsi-
ble for the lack of improved whole body glucose recovery after estrogen replacement.
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n = 4). Data are expressed as mean ± SD, no significant differences are detected.
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ArKO (KOP).Whole body glucose tolerance tests (GTT) were completed on fasted 6 month-
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